Plain-English translation of NCT07295223 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether two medications—dapagliflozin and semaglutide—can help reduce inflammation in your body after a heart attack. Both medications are already used to treat diabetes and heart conditions, but researchers want to see if they work together to lower dangerous inflammatory markers in your blood over 24 weeks. The study will measure specific inflammation signals before and after treatment to understand if this medication combination helps your recovery.
After a heart attack, your body's inflammatory response can cause additional damage and increase your risk of future heart problems. This trial is testing whether this medication combination can lower that harmful inflammation and potentially improve outcomes for heart attack patients.
You likely qualify if…
You likely don't qualify if…
You would start taking the two medications shortly after your emergency heart attack treatment. You'll take dapagliflozin as a daily 10 mg pill, while semaglutide will start at a lower dose and gradually increase over the 24 weeks. During this time, researchers will check your blood inflammation levels when you're admitted and again after 24 weeks to see if the medication combination is working. Your doctor will monitor how well you're tolerating the medications and ensure you're taking them as prescribed.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Mexico